CN119817810A

CN119817810A - Formula food with special medical application and preparation method and application thereof

Info

Publication number: CN119817810A
Application number: CN202510090981.1A
Authority: CN
Inventors: 李奋昕; 李艳杰; 王学敏; 关尚玮; 孔小宇; 刘彪; 段素芳; 司徒文佑; 何剑
Original assignee: Inner Mongolia Yili Industrial Group Co Ltd
Current assignee: Inner Mongolia Yili Industrial Group Co Ltd
Priority date: 2025-01-21
Filing date: 2025-01-21
Publication date: 2025-04-15

Abstract

The present invention provides a special medical purpose formula food and a preparation method and application thereof, which contains DHA, ARA and a neuraminic acid composition, wherein the mass ratio of DHA to ARA is 0.2-5:1, and the mass ratio of the total amount of DHA and ARA to neuraminic acid is 0.8-20:1; wherein, based on the dry matter weight of the special medical purpose formula food, the protein content is 10-16g/100g, the fat content is 21-32g/100g, and the carbohydrate content is 50-58g/100g, which has the effect of effectively enhancing and/or improving the social behavior of an individual.

Description

Formula food with special medical application and preparation method and application thereof

Technical Field

The invention relates to the technical field of functional nutrient research, in particular to a formula food with special medical application, and a preparation method and application thereof.

Background

The early life is the fastest period of organism development, and the childhood stage is the healthy development golden period of the whole life stage, and it is very critical to ensure the steady healthy development of children. Balancing the effects of nutrition on healthy development is most important. DHA (docosahexaenoic acid), ARA (arachidonic acid) and nervonic acid are three important polyunsaturated fatty acids. DHA is a fatty acid that is mainly present in the brain, nervous tissue and retina. It not only constitutes an important component of these tissues, but also helps to maintain the fluidity and stability of the cell membrane. ARA is also an important fatty acid in the brain, involved in the structure and function of nerve cells. Nervonic acid, a specific fatty acid, is an important component of white matter of the brain and is essential for the health and development of the nervous system. In the current state of the art, DHA, ARA and nervonic acid are commonly added, alone or in combination, to infant or child formulas or nutrition to enhance their nutritional functional value. However, the effects of DHA, ARA and nervonic acid on brain function are mostly focused on the effects of single components, but there are relatively few studies on the combined effects of these components, and further, how to optimize the addition ratio and mode of these components to achieve the best nutritional effect, and there is still no intensive study.

Social behavior (social behavior) refers to the ability of individuals to communicate with surrounding people and life self-care, and is incorporated into one of the evaluation dimensions of WS/T580-2017, 0-6-year-old child development behavior evaluation Scale. The early childhood is the sensitive period and the critical period of the social behavior development of the individual, and the development of good social behavior has long-term influence on the healthy growth and socialization process of the child and has great significance on the development of other adaptability of the individual.

After searching, whether diet affects the social behavior of the individual or not and how it affects the social behavior of the individual are rarely reported in the prior art.

Disclosure of Invention

In order to solve the technical problems, the invention aims to provide a formula food with special medical application, a preparation method and application thereof, and the formula food contains DHA, ARA and a nervonic acid composition and has the effect of effectively improving and/or improving the social behaviors of individuals.

To achieve the above object, the present invention provides a formulation for special medical use, which comprises DHA, ARA and a composition of nervonic acid, wherein the mass ratio of DHA to ARA is 0.2-5:1, and the mass ratio of the total amount of DHA and ARA to nervonic acid is 0.8-20:1;

Wherein the special medical use formula comprises 10-16g/100g protein content, 21-32g/100g fat content and 50-58g/100g carbohydrate content based on dry matter of the special medical use formula, and the special medical use formula is selected from one or more of lactose-free or low lactose formula, partially hydrolyzed formula of infant milk protein, deeply hydrolyzed formula of infant milk protein, infant amino acid formula, premature/low birth weight infant formula, breast milk nutritional supplement, infant amino acid metabolic disorder formula, food protein allergy complete nutritional formula, inflammatory bowel disease complete nutritional formula, gastrointestinal tract absorption disorder complete nutritional formula, and fatty acid metabolism disorder complete nutritional formula.

According to a specific embodiment of the invention, the weight ratio of DHA to ARA in the formula for special medical use according to the invention is 0.3-3:1, and the weight ratio of the total amount of DHA and ARA to the nervonic acid is 0.8-20:1.

According to some embodiments of the invention, the mass ratio of DHA to ARA in the special medical use formula according to the invention is preferably 0.5-2.5:1.

According to some embodiments of the invention, the mass ratio of DHA to ARA in the special medical use formula according to the invention is preferably 0.5-2:1.

According to some embodiments of the invention, the mass ratio of DHA to ARA in the special medical use formula according to the invention is preferably 0.5-1.5:1, such as 0.5:1,0.6:1,0.67:1,0.8:1,1:1,1.1:1,1.2:1,1.3:1 or 1.4:1.

According to some embodiments of the invention, the mass ratio of the total amount of DHA and ARA to the nervonic acid in the special medical use formula according to the invention is 0.8-10:1.

According to some embodiments of the invention, the mass ratio of the total amount of DHA and ARA to the nervonic acid in the special medical use formula according to the invention is 0.8-8:1.

According to some preferred embodiments of the invention, the mass ratio of DHA and ARA to nervonic acid in the special medical use formula according to the invention is 0.8-5:1, further preferred 0.8-3:1, such as 0.9:1,1:1,1.1:1,1.2:1,1.3:1,1.5:1,2:1,2.5:1 or 3:1.

According to some embodiments of the invention, the mass ratio of the total amount of DHA and ARA to the nervonic acid in the special medical use formula according to the invention is 10-20:1, such as 10:1,11:1,12:1,13:1,14:1,15:1,16:1,17:1,18:1,19:1 or 20:1.

In the formula food with special medical application, the DHA can be DHA grease and/or powder derived from one or more than two of algae, tuna oil, fish oil, feed nutrition regulating bioconversion milk source DHA, yolk extract and krill oil, wherein the algae can be one or more than two of schizochytrium limacinum, ukenella and Crypthecodinium cohnii. The ratio of DHA to other functional components in the formula for special medical uses according to the invention is based on the DHA content of the raw material, unless otherwise noted.

In the above specific medical use formula, the raw material providing the ARA may be one or more raw materials derived from algae and other ARA-containing oils. The ratio of ARA to other functional components in the special medical use formula of the present invention is based on the ARA content of the starting materials, unless otherwise noted.

In the above formula food with special medical application, the raw material for providing the nervonic acid can be one or more than two of nervonic acid from cis-15-tetracosenoic acid, acer truncatum seed oil, nervonic acid synthesized by microbial fermentation method and other oils containing nervonic acid. The ratio of said nervonic acid to other functional components in the special medical use formula of the present invention is based on the amount of nervonic acid in the starting material, unless otherwise noted.

According to a specific embodiment of the invention, the special medical use formula according to the invention contains ARA in an amount of 10-420mg/100g dry matter of the food, based on the amount of ARA in the composition.

According to some embodiments of the invention, the special medical use formula of the invention comprises ARA in an amount of 10-200mg/100g dry matter of the food, based on the amount of ARA in the composition. According to some more specific embodiments of the invention, the special medical use formula of the invention comprises ARA in an amount of about 30, about 60mg/100g dry matter, about 65mg/100g dry matter, about 85mg/100g dry matter, about 120mg/100g dry matter, about 150mg/100g dry matter, based on the amount of ARA in the composition.

According to some embodiments of the invention, the special medical use formula of the invention comprises ARA in an amount of 15-400mg/100g dry matter of the food, based on the amount of ARA in the composition.

In some embodiments of the invention, the special medical use formula of the invention comprises ARA in an amount of 20-150mg/100g dry matter, 100-200mg/100g dry matter, 200-300mg/100g dry matter or 300-400mg/100g dry matter of ARA in the food based on the amount of ARA in the composition.

In some embodiments of the invention, the content of DHA and nervonic acid in the special medical use formula of the invention can be determined according to the ratio with ARA.

In the above special medical use formula, preferably, the special medical use formula contains ARA in an amount of 10-420mg/100g dry matter of food, preferably, the special medical use formula contains ARA in an amount of 15-400mg/100g dry matter of food, based on the amount of ARA in the DHA, ARA and nervonic acid composition.

According to a specific embodiment of the invention, the fat-providing raw materials in the special medical use formula according to the invention comprise, in addition to the milk fat-containing base raw materials, vegetable oils which may include, but are not limited to, one or more of sunflower oil, corn oil, soybean oil, canola oil, coconut oil, palm oil, walnut oil, acer truncatum seed oil, preferably sunflower oil, corn oil, acer truncatum seed oil and soybean oil, the addition of which provides on the one hand the fat component to the product and on the other hand linoleic acid, alpha-linolenic acid, and at the same time nervonic acid, the nervonic acid content of acer truncatum seed oil being typically between 5% and 10%. In addition, the fat-providing raw material may optionally include medium chain triglycerides, and a raw material OPO structured fat added for providing 1, 3-dioleoyl-2-palmitoleic acid triglyceride. Since the purity of the OPO structured lipid raw materials sold in the market at present is different, namely the content of the effective component 1, 3-dioleoyl-2-palmitic acid triglyceride is different, and is usually about 40% -70%, in the invention, the term "1, 3-dioleoyl-2-palmitic acid triglyceride" is adopted when describing the effective component, and the common name "OPO structured lipid" is adopted when describing the food raw materials for providing the effective component 1, 3-dioleoyl-2-palmitic acid triglyceride. The specific addition amount of OPO structural fat can be converted according to the content requirement of the 1, 3-dioleoyl-2-palmitic acid triglyceride in the milk powder product of the invention and the purity of OPO structural fat raw material. More preferably, the formula food for special medical use comprises, based on 1000 parts by weight, 5-100 parts by weight of acer truncatum seed oil, 0-150 parts by weight of sunflower seed oil, 0-50 parts by weight of corn oil, 0-80 parts by weight of soybean oil, 0-100 parts by weight of canola oil, 0-150 parts by weight of medium chain triglyceride and 0-140 parts by weight of OPO structural fat.

According to a specific embodiment of the present invention, the carbohydrate is derived from lactose or non-lactose sources, including but not limited to pregelatinized starch, maltodextrin, solid corn syrup, glucose syrup, and in part from modified starch-based emulsifiers, in special medical-use formulas as described herein. That is, in the special medical use formula of the present invention, the carbohydrate-providing raw materials include, but are not limited to, raw lactose, emulsifiers and pre-hydrolyzed or gelatinized starch-based materials in addition to lactose-containing base materials. Preferably, the raw materials of the formula food for special medical use comprise, but are not limited to, 0-580 parts by weight of lactose and 0-580 parts by weight of non-lactose substances based on 1000 parts by weight of the formula food for special medical use. The specific addition amount of lactose may be adjusted within the range so that the carbohydrate content of the present invention is 50 to 58g/100g.

According to a specific embodiment of the present invention, the raw materials of the special medical formula food further comprise, but not limited to, one or more of proper DHA, ARA, EPA, nucleotide, lactoferrin, etc., and further comprise compound nutrients comprising calcium powder, vitamins and minerals. Preferably, the formula food for special medical use according to the invention comprises, based on 1000 parts by weight, 1-20 parts by weight of DHA, 2-30 parts by weight of ARA, 10-140 parts by weight of EPA and 7-70 parts by weight of compound nutrients comprising calcium powder, vitamins and minerals.

More preferably, the special medical use formula is an infant milk protein partially hydrolyzed formula or an infant milk protein deep hydrolyzed formula, wherein the total protein in the infant milk protein partially hydrolyzed formula comprises hydrolyzed milk protein and the protein having a molecular weight distribution of 1000dal or less comprises 30% or more, typically less than 70%, preferably 40% or more, typically less than 70% of the total protein, and the total protein in the infant milk protein deep hydrolyzed formula comprises hydrolyzed milk protein and the protein having a molecular weight distribution of 1000dal or less comprises 70% or more, preferably 80% or more of the total protein.

Further preferably, the raw materials comprise, based on 1000 parts by weight of the infant milk protein partially hydrolyzed formula:

It will be appreciated that in a formula for a particular medical use according to the invention, the specific amounts of the ingredients should be determined by adjusting the amounts of ingredients to meet the requirements for the formula product. In a special medical use formula of the invention, the product performance indexes which are not specified or listed in detail are all implemented according to the standards of infant formulas or prepared milk powder and the regulations of related standards and regulations.

In the formula food with special medical application, all raw materials can be obtained commercially, and the selection of the raw materials meets the requirements of relevant standards. In addition, the compound nutrient can also be self-compounded. The invention adopts 'compound' for convenience of expression, and does not mean that all components in the compound are mixed together and then applied. All raw materials should be added and used on the premise of meeting related regulations.

Further preferably, the raw materials comprise, based on 1000 parts by weight of the infant milk protein deep hydrolysis formula:

It will be appreciated that a particular medical use formula of the present invention is one in which the specific amounts of the ingredients are adjusted to meet the requirements for the formula product. In a special medical use formula of the invention, the product performance indexes which are not specified or listed in detail are all implemented according to the standards of infant formulas or prepared milk powder and the regulations of related standards and regulations.

In the formula food with special medical application, the compound nutrients are combinations of nutrient components meeting the standard, and different addition amounts are used according to different formulas. The formula milk powder can selectively adopt any one or any combination of the following compound nutrient components if nutrients are added according to the needs. In the above special medical use formula food, preferably, the compound nutrients comprising calcium powder, vitamins and minerals are used in the following amounts:

Component 1, compound vitamin, wherein each gram of compound vitamin comprises the following components:

25-340 mg of taurine;

1700-5800 mu gRE of vitamin A;

25-70 mug of vitamin D;

2000-6800 mug of vitamin B ₁;

3000-6900 mug of vitamin B ₂;

1700-4000 mug of vitamin B ₆;

8-20 mug of vitamin B ₁₂;

200-700 mug of vitamin K ₁;

0-700 mg of vitamin C;

10-70 mg of vitamin E and alpha-TE;

10000-41550 mug of nicotinamide;

350-920 mug of folic acid;

70-245 mug of biotin;

7100-25230 mug pantothenic acid;

0-250mg of inositol;

0-60mg of L-carnitine;

component 2, mineral two, wherein each gram of mineral two:

40-100 mg of sodium;

200-500 mg of potassium;

component 3, mineral three, wherein in every gram of mineral two:

200-500 mg of calcium;

75-300 mg of phosphorus;

component 4, mineral one, wherein each gram of mineral one:

20-110 mg of iron;

23-90 mg of zinc;

2000-4180 mug of copper;

500-995 mug of iodine;

Selenium is 0-200 mug;

Manganese 0-579 mug;

component 5, compounding magnesium chloride, wherein in each gram of magnesium chloride:

80-170 mg of magnesium;

component 6, choline chloride, wherein in each gram of choline chloride:

200-950 mg of choline.

The base material of the compound nutrient containing calcium powder, vitamins and minerals is preferably lactose, solid corn syrup or L-sodium ascorbate. Based on 1000 parts by weight of the formula food with special medical application, the addition amount of the compound nutrient containing the calcium powder, the vitamin and the mineral is 7-70 parts by weight, wherein the component 1 is preferably 2-8 parts by weight, the component 2 is preferably 2-40 parts by weight, the component 3 is preferably 0.5-40 parts by weight, the component 4 is preferably 0.5-6 parts by weight, the component 5 is 0-7 parts by weight, the five-component 6 is 0-3 parts by weight, and the base material of each component is preferably maltodextrin or L-sodium ascorbate.

The compound materials used in the components to provide the nutrient substances may have interactions. For example, sulfate can accelerate the oxidative destruction process of vitamins, which can reduce their utilization. Because sulfate occurs in ionic form in aqueous solution, it acts as an oxidizing agent to induce oxidation of vitamins during the oxidation reaction, thereby destroying the vitamin structure. The trace elements have different capacities in oxidation-reduction reaction, and the activities of copper, zinc and iron are strongest, and manganese and selenium are used for times. Vitamins B and vitamin C are susceptible to copper ions and vitamin B ₂ is susceptible to iron ions.

In order to ensure the utilization efficiency of nutrient substances, a stable nutrient formulation is selected, for example, vitamin A is selected from retinol acetate, retinol contains 1 hydroxyl group and 5 double bonds and is easy to oxidize, but the stability of the retinol is improved greatly under the form of acetate, vitamin E is selected from tocopheryl acetate, the tocopherol is also unstable, but the stability of the tocopheryl acetate is improved greatly, vitamin B ₁ is selected from thiamine nitrate, the thiamine nitrate is more stable than thiamine hydrochloride in the existing form of thiamine, and vitamin C is selected from L-sodium ascorbate.

The component contents of the compound nutrient containing the calcium powder, the vitamins and the minerals refer to the additive amount for strengthening the nutrient substances, and the content of the nutrient components in other raw materials of the milk powder is not included.

The invention also provides a preparation method of the special medical use formula food, wherein the method comprises the steps of adopting a wet or dry production process to mix DHA, ARA and nervonic acid composition with other raw materials in the special medical use formula food to prepare the special medical use formula food;

preferably, the method comprises the following steps:

The method comprises the steps of S01 mixing, namely uniformly adding various powder raw materials into a powder mixing tank through an air conveying system according to a formula after metering, obtaining powder raw materials to be subjected to vacuum powder absorption, sucking the powder raw materials to be subjected to vacuum powder absorption in the powder mixing tank into a vacuum mixing tank through a vacuum system, putting grease specified in the formula into a melting tank according to the formula requirement, keeping the temperature of the melting tank at 50-90 ℃, pumping the melted grease into a mixed oil storage tank according to the formula proportion requirement after the oil is melted, obtaining mixed oil, keeping the mixed oil in an oil storage tank for storage at 40-50 ℃ for 0-12 hours, preventing fat oxidation, pumping the mixed oil into the mixing tank according to the formula requirement, respectively adding calcium powder, mineral substances, vitamins and the like, pumping into a wet mixing tank after respectively dissolving, flushing an adding tank and a pipeline with 50-150 kg pure water, and obtaining mixed feed liquid;

S02, filtering the mixed feed liquid through a filter screen to remove physical impurities possibly carried in the feed liquid to obtain filtered feed liquid;

S03, homogenizing the filtered feed liquid through a homogenizer, wherein the primary pressure of the homogenization is 105+/-5 bar, the primary pressure of the homogenization is 32+/-3 bar, mechanically treating the fat globules, and dispersing the fat globules into uniform fat globules to obtain homogenized feed liquid;

S04, cooling and sterilizing, namely cooling the homogenized feed liquid to 5-20 ℃, temporarily storing the homogenized feed liquid in a pre-storing cylinder for 0-6 hours, entering the next process, starting a stirrer according to set requirements, concentrating by using double effects during production, sterilizing at a temperature of more than or equal to 83 ℃, sterilizing for 25 seconds, and obtaining concentrated milk with discharge concentration of 48-52% of dry matter;

S05, storing concentrated milk, preheating, filtering and spray drying, namely temporarily storing the concentrated milk in a concentrated milk balance tank, preheating to 60-70 ℃ through a scraper preheater, filtering the preheated material through a filter with the aperture of 0.5-1.5 mm, pumping the material into a drying tower for spray drying by using a high-pressure pump, agglomerating fine powder on the top of the tower or a fluidized bed according to requirements, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 75-90 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is-4 to-2 mbar;

S06, fluidized bed drying and cooling, namely, after powder from a drying tower is subjected to fluidized bed (primary) secondary drying, cooling to 25-30 ℃ through a fluidized bed (secondary), mixing human milk oligosaccharide and a carrier, heating to 60-65 ℃, uniformly dispersing the mixture on the surface of the powder under the action of compressed air, weighing DHA, ARA, nucleotide and bifidobacterium, sealing bags and subpackaging according to the formula requirement, and obtaining weighed DHA, ARA, nucleotide and bifidobacterium;

and S07, sieving, namely uniformly mixing the weighed DHA, ARA, nucleotide, bifidobacterium and milk powder in a dry mixer, uniformly granulating the milk powder by a vibrating screen, scrapping powder residues, collecting the powder by a sterilized powder collecting box, and transporting the powder from a powder outlet room to a powder feeding room to obtain the formula food with special medical use.

The invention also provides the application of the special medical formula food in preparing a product which is helpful for improving and/or improving the social behavior of individuals.

In the above application, preferably, the enhancing and/or improving the social behavior of the individual comprises enhancing the social willingness and/or social ability of the individual;

more preferably, the social capacity includes social interaction capacity and/or social adaptation capacity (the capacity of an individual to react and adapt to its surrounding social environment and/or social needs).

In the above application, preferably, the individual is an infant or young child.

According to a specific embodiment of the present invention, the product of the present invention may be a general food or a functional food. The invention does not require special requirements for the specific form of the product, for example, the leisure food can be milk slices, candies and the like, and the nutritional supplement, the dietary supplement health food or the special medical purpose formula food and the like can be in the form of oral liquid, powder, capsules and the like.

According to a specific embodiment of the invention, the product according to the invention is a dairy product, such as an infant formula, a milk powder, a milk tablet, a cheese, a liquid dairy product, a complementary food or a nutritional supplement. The product of the present invention is not limited to foods for infants or children, but may be foods for adults or middle aged and elderly people.

It will be appreciated that the content of each functional substance in the final product should be appropriately adjusted within the limits allowed by the relevant standard specifications for different kinds of products.

According to some embodiments of the present invention, the product may be any of the aforementioned foods, or foods prepared by reprocessing the aforementioned special medical use formula foods as raw materials, with no or additional substances added.

In the present invention, unless otherwise noted, the infant is an infant of 0 to 12 months of age, and the infant refers to an infant of 1 to 3 years of age.

This definition applies to all parts of the present invention that relate to "infants" and "young children" to ensure that the technology, product or method of the present invention meets the safety standards and applicability of infant use. The design and use parameters of specific products or equipment can be properly adjusted according to the characteristics of different age groups so as to ensure the safety and effectiveness of the products or equipment.

The invention has the following beneficial technical effects:

The present invention provides a method of designing a nutritional composition in a special medical use formula that helps to promote and/or improve social behaviour in an individual, the special medical use formula having the effect of promoting and/or improving social behaviour in an individual. The composition of DHA, ARA and nervonic acid contained in the formula food with special medical application can influence the social behavior of an individual, and the DHA, ARA and nervonic acid are combined according to a certain proportion to have a synergistic effect on improving and/or improving the social behavior of the individual.

Drawings

Fig. 1 shows the detection results of the approach frequency of each experimental group.

Fig. 2 shows the detection result of the approach accumulated time of each experimental group experimental example.

Fig. 3 shows the detection results of the body contact frequency of each experimental group experimental example.

Fig. 4 shows the results of detection of the body contact cumulative time of each experimental group experimental example.

Fig. 5 shows the detection results of the relative movement frequency of each experimental group experimental example.

Fig. 6 shows the detection results of the relative movement integrated time of each experimental group experimental example.

Detailed Description

The technical solution of the present invention will be described in detail below for a clearer understanding of technical features, objects and advantageous effects of the present invention, but should not be construed as limiting the scope of the present invention.

Before further describing embodiments of the invention, it is to be understood that the scope of the invention is not limited to the specific embodiments described below, and that the terminology used in the examples of the invention is intended to be in the nature of specific embodiments and is not intended to be limiting of the scope of the invention.

Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

In addition to the specific methods, devices, materials used in the embodiments, any methods, devices, and materials of the prior art similar or equivalent to those described in the embodiments of the present invention may be used to practice the present invention according to the knowledge of one skilled in the art and the description of the present invention.

Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all employ techniques conventional in the art.

In the examples and experiments, DHA, ARA and nervonic acid are all commercial food grade materials, and the DHA, ARA and nervonic acid are all effective contents of the functional components DHA, ARA and nervonic acid in the materials except special notes.

Example 1 an infant milk protein partially hydrolyzed formula (preparation of 1000 kg) containing a nutritional composition that aids in improving and/or improving social behavior in an individual, the total protein in the infant milk protein partially hydrolyzed formula comprising hydrolyzed milk protein, and a protein having a molecular weight distribution of 1000dal or less comprising 30% or more of the total protein:

155 kg of hydrolyzed whey protein powder, 270kg of lactose, 270kg of solid corn syrup, 90 kg of high oleic acid sunflower seed oil, 50 kg of acer truncatum seed oil, 60 kg of soybean oil, 80 kg of OPO structural fat, 38 kg of compound nutrient, 3 kg of DHA, 7 kg of ARA, 0.1 kg of bifidobacterium and 0.65 kg of nucleotide.

Wherein the compound nutrients comprise about 3.0 kg of compound vitamin nutrition package, about 2.0 kg of choline chloride nutrition package, about 12 kg of calcium powder nutrition package, 16 kg of sodium potassium nutrition package, about 2 kg of mineral nutrition package and about 3.0 kg of magnesium chloride nutrition package, and the base material of each nutrition package is maltodextrin.

Wherein the protein content of the product is 13.5g/100g, the fat content is 28g/100g, the carbohydrate content is 54g/100g, the DHA content is 100mg/100g, the ARA content is 220mg/100g, and the nervonic acid content is 400mg/100g. DHA and ARA ratio of 0.45:1, and DHA and ARA ratio of 0.8:1.

The process for preparing a partially hydrolyzed infant milk protein formula containing a nutritional composition that helps to promote and/or improve social behavior in an individual is as follows:

1) Powder adding, namely uniformly adding various powder raw materials into a powder preparation tank for storage through an air conveying system after metering according to a formula to obtain the powder raw materials to be subjected to vacuum powder suction;

2) Vacuum powder suction, namely sucking powder raw materials to be subjected to vacuum powder suction in a powder preparation tank into a vacuum mixing tank through a vacuum system;

3) Dissolving and oil distribution, namely placing grease specified in a formula into an oil dissolving room according to the formula requirement, keeping the temperature of the oil dissolving room at 70 ℃, and pumping the oil into a mixed oil storage tank according to the formula proportion requirement after the oil is dissolved to obtain mixed oil;

4) And (3) storing the mixed oil, namely storing the mixed oil in an oil storage tank in a heat-preserving way at the temperature of 45 ℃ for 6 hours to prevent fat oxidation.

5) Weighing, namely pumping the mixed oil into a mixing tank through an oil pump according to the formula requirement.

6) The nutrients are dissolved and added, namely calcium powder, minerals, vitamins and the like are respectively added, 150kg of purified water is used for dissolving the calcium powder, the minerals, the vitamins and the like, and the mixture is put into a wet mixing tank, and an adding tank and a pipeline are flushed with 150kg of purified water after each time.

7) Filtering, namely filtering the mixed feed liquid through a filter screen to remove physical impurities possibly carried in the raw materials, thereby obtaining the filtered feed liquid.

8) Homogenizing, namely homogenizing the filtered feed liquid by a homogenizer, wherein the primary pressure of the homogenizing is 105bar, the primary pressure of the homogenizing is 32bar, mechanically treating the fat globules, and dispersing the fat globules into uniform fat globules to obtain the homogenized feed liquid.

9) Cooling and storing, namely cooling the homogenized feed liquid in a plate heat exchanger to 15 ℃, temporarily storing in a pre-storing cylinder, entering the next working procedure after 1 hour, and starting a stirrer according to set requirements.

10 Concentrating and sterilizing, namely concentrating by double effects during production, wherein the sterilization temperature is 85 ℃ and the sterilization time is 25 seconds. The concentration of the discharged materials is 48% of dry matters, and the concentrated milk is obtained.

11 Storing concentrated milk, preheating, filtering, spray drying, and temporarily storing the concentrated milk in a concentrated milk balance tank. Preheating to 65deg.C by scraper preheater, filtering with 1mm pore size filter, spray drying by high pressure pump, and agglomerating fine powder on top of tower or fluidized bed. The inlet air temperature is 170 ℃, the exhaust air temperature is 80 ℃, the pressure of the high-pressure pump is 190bar, and the negative pressure of the tower is-3 mbar.

12 Drying and cooling the fluidized bed, namely cooling the powder from the drying tower to 25 ℃ through the fluidized bed (the second stage) after the powder is subjected to secondary drying through the fluidized bed (the first stage). Meanwhile, the human milk oligosaccharide is heated to 62 ℃ after being mixed with the carrier, and is uniformly dispersed on the surface of the powder under the action of compressed air, so that the particle size and the quick solubility of the powder particles are increased by agglomeration.

13 And (3) subpackaging, namely weighing DHA, ARA, nucleotide and bifidobacterium by personnel in a powder making workshop according to the formula requirement, and subpackaging by sealing bags to obtain the weighed DHA, ARA, nucleotide and bifidobacterium.

14 Dry mixing, namely uniformly mixing the weighed DHA, ARA, nucleotide, bifidobacterium and milk powder in a dry mixer.

15 Screening powder, namely uniformly granularity of the milk powder through a vibrating screen, and scrapping powder slag.

16 Powder discharge, namely, powder is received by a sterilized powder collecting box and is transported to a powder feeding room from a powder discharging room.

17 Powder feeding, namely pouring the milk powder into a powder storage tank on a size packaging machine according to the packaging requirement.

18 Packaging 800 g of nitrogen-filled package of the automatic packaging machine. The oxygen content is lower than 1% when nitrogen is filled. 900 g of iron can is automatically filled with nitrogen and packaged, and the oxygen content is lower than 5%.

19 Packaging, namely packaging the packaged small bags into a carton, adding a powder spoon at the same time, and sealing by a box sealing machine.

20 And (3) finished product inspection, namely sampling inspection is carried out on the packaged product according to an inspection plan.

21 Warehousing, namely warehousing and storing the qualified products, wherein the products are required to be stored at normal temperature, and the humidity is less than or equal to 65 percent.

The prepared product meets the requirements of related standards or specifications.

Example 2 an infant milk protein partially hydrolyzed formula (preparation of 1000 kg) containing a nutritional composition that aids in improving and/or improving social behavior in an individual, the total protein in the infant milk protein partially hydrolyzed formula comprising hydrolyzed milk protein, and a protein having a molecular weight distribution of 1000dal or less comprising 30% or more of the total protein:

160 kg of hydrolyzed whey protein powder, 270kg of lactose, 270kg of solid corn syrup, 80 kg of high oleic sunflower seed oil, 10 kg of acer truncatum seed oil, 80 kg of soybean oil, 90 kg of OPO structural fat, 38 kg of compound nutrient, 5.5 kg of DHA, 6.5 kg of ARA, 0.1 kg of bifidobacterium and 0.65 kg of nucleotide.

Wherein the protein content of the product is 14g/100g, the fat content is 26g/100g, the carbohydrate content is 54g/100g, DHA is 180mg/100g, ARA is 190mg/100g, and nervonic acid is 80mg/100g. DHA and ARA ratio of 0.95:1, and DHA and ARA ratio of 4.6:1.

The process for preparing infant milk protein deep hydrolysis formula containing nutritional compositions that help to enhance and/or improve social behaviour of individuals is the same as in example 1.

Example 3 infant milk protein deep-hydrolyzed formula (preparation of 1000 kg) containing nutritional compositions that help promote and/or improve social behavior in individuals, the total protein in the infant milk protein deep-hydrolyzed formula comprises hydrolyzed milk protein, and the protein having a molecular weight distribution of 1000dal or less comprises 70% or more of the total protein:

175 kg of hydrolyzed whey protein powder, 500 kg of maltodextrin, 50 kg of soybean oil, 10 kg of acer truncatum seed oil, 160 kg of medium chain triglyceride, 50 kg of OPO structural fat, 55 kg of compound nutrient, 6.5 kg of DHA and 13 kg of ARA.

Wherein the compound nutrients comprise about 4 kg of compound vitamin nutrition package, about 4 kg of choline chloride nutrition package, about 20 kg of calcium powder nutrition package, 19 kg of sodium potassium nutrition package, about 4 kg of mineral nutrition package and about 4 kg of magnesium chloride nutrition package, and the base material of each nutrition package is maltodextrin.

Wherein the protein content of the product is 15.3g/100g, the fat content is 27g/100g, the carbohydrate content is 50g/100g, the DHA is 200mg/100g, the ARA is 400mg/100g, and the nervonic acid is 80mg/100g. DHA and ARA ratio of 0.5:1, and DHA and ARA ratio of 7.5:1.

The process for preparing a deep hydrolyzed infant formula containing nutritional compositions that help to enhance and/or improve social behavior in individuals is as follows:

4) And (3) storing the mixed oil, namely storing the mixed oil in an oil storage tank in a heat-preserving way at the temperature of 45 ℃ for less than 12 hours to prevent fat oxidation.

9) Cooling and storing, namely cooling the homogenized feed liquid in a plate heat exchanger to 16 ℃, temporarily storing in a pre-storing cylinder, entering the next working procedure after 1 hour, and starting a stirrer according to set requirements.

10 Concentrating and sterilizing, namely concentrating by double effects during production, sterilizing at 83 ℃ for 25 seconds. The concentration of the discharged materials is 50% of dry matters, and the concentrated milk is obtained.

11 Storing concentrated milk, preheating, filtering, spray drying, and temporarily storing the concentrated milk in a concentrated milk balance tank. Preheating to 65deg.C by scraper preheater, filtering with 1mm pore size filter, spray drying by high pressure pump, and agglomerating fine powder on top of tower or fluidized bed. The inlet air temperature is 175 ℃, the exhaust air temperature is 80 ℃, the pressure of the high-pressure pump is 200bar, and the negative pressure of the tower is-3 mbar.

12 Drying and cooling the fluidized bed, namely cooling the powder from the drying tower to 30 ℃ through the fluidized bed (the second stage) after the powder is subjected to secondary drying through the fluidized bed (the first stage). Meanwhile, the human milk oligosaccharide is heated to 60 ℃ after being mixed with the carrier, and is uniformly dispersed on the surface of the powder under the action of compressed air, so that the particle size and the quick solubility of the powder particles are increased by agglomeration.

Example 4 infant milk protein deep-hydrolyzed formula (preparation of 1000 kg) containing nutritional composition to aid in improving and/or improving social behavior in individuals, the total protein in the infant milk protein deep-hydrolyzed formula comprising hydrolyzed milk protein, and a protein having a molecular weight distribution of 1000dal or less comprising 70% or more of the total protein:

175 kg of hydrolyzed whey protein powder, 330 kg of maltodextrin, 210 kg of glucose syrup, 30 kg of acer truncatum seed oil, 110 kg of soybean oil, 80 kg of medium chain triglyceride, 30 kg of OPO structural fat, 55 kg of compound nutrient, 3.5 kg of DHA and 6 kg of ARA.

Wherein the protein content of the product is 15.3g/100g, the fat content is 25g/100g, the carbohydrate content is 54g/100g, DHA is 120mg/100g, ARA is 180mg/100g, and nervonic acid is 240mg/100g. DHA and ARA ratio of 0.67:1, and DHA and ARA ratio of 1.25:1.

The process for preparing infant milk protein deep hydrolysis formula containing nutritional compositions that help to enhance and/or improve social behaviour of individuals is the same as in example 3.

Efficacy experiment of nutritional composition for improving social ability

1. Bee variety and grouping

The intervention patterns of the different experimental groups based on the diet of the feed bees are shown in table 1, using 1 day old italian bees (APIS MELLIFERA).

TABLE 1

2. Basic bee culture

2.1 Preparation of diet

The diet preparation of the control group comprises weighing 500g sucrose and 10g casein hydrolysate, adding ultrapure water to volume of 1L, stirring for dissolving, filtering with a filter membrane with aperture of 0.22 μm for sterilization, and obtaining 50% (w/v) sucrose solution containing 1% (w/v) casein hydrolysate required by experiment.

Treatment group diet free diet group added treatment reagent based on control group diet, single feeding group metered with sugar water with daily diet of 40 μl of each bee, and one-time concentrating reagent to 5 μl of sterile sugar water for feeding.

2.2 Bee picking

(1) Bee spleen selection

The honeycombs with proper age are selected from the bee field, quickly transported back to the laboratory, and cultured in an incubator (DHP-9162 constant temperature incubator of science and technology Co., ltd. In China) with the temperature of 35 ℃ and the humidity of 60-80%.

(2) Bee picking

The condition of the eclosion bees is observed every day after the second day (if the bees are not eclosion, the eclosion bees are continuously cultivated), the eclosion bees are gently taken out by tweezers and are split into disposable transparent culture cups, 30 bees are split into enough cups according to experimental requirements.

2.3 Pretreatment of bees

(1) Preparation of intestinal juice

Directly taking eclosion worker bees from a bee field, extracting intestinal tracts, adding 100 mu L of PBS buffer solution into each intestinal tract, grinding, adding 50% glycerol into the mixture at a ratio of 1:1, and preserving at-80 ℃.

(2) Intestinal canal liquid field planting

Taking a sterile 2mL centrifuge tube, adding 990 mu L of sterile PBS buffer solution, adding 10 mu L of working bee intestine solution, uniformly mixing, finally, using 50% (w/v) sterile sucrose solution to fix the volume to a 2mL scale, and vibrating and uniformly mixing. Feeding 1 tube of the mixed solution to each newly emerged bee, and continuously placing the bees in a constant temperature incubator for culturing for 24 hours.

2.4 Treatment feeding

And after the intestinal canal liquid field planting is finished, starting to feed the treatment, feeding CV diet to CV groups, and feeding the treatment diet to the treatment groups. The treatment feeding is carried out for 7 continuous days, the growth state of bees is observed every day and the diet is replaced in time, ensuring adequate diet. The culture condition is darkness, 35 ℃ and 60-80% humidity.

If the feeding is carried out by single feeding, the diets placed in the feeding cup are CV diets, and different treatment reagents are added into the single feeding diet.

3. Experimental detection

Social ability detection:

(1) The behavior observation room is prepared by opening an air conditioner and an exhaust fan of a test bed 1-2 hours before the experiment, keeping the temperature (26 ℃) of the observation room constant, and no peculiar smell exists in the test bed.

(2) Every 3 experimental bees were placed in a transparent breathable open field prepared in advance.

(3) The open field is static to adapt to 15 minutes at the laboratory bench, carries out video shooting to the open field from directly over, continuously shoots 45 minutes.

(4) And analyzing the video through an Etho Vision XT 17 animal social behavior analysis system to obtain animal social behavior capacity data, and performing social behavior evaluation from 2 dimensions of social interaction trend evaluation and social interaction evaluation.

4. Experimental results

(1) Social interaction trend evaluation results

Social interaction tendencies assessment is the frequency, time, etc. of experimental animals approaching each other but not social behavior, and the present invention uses the frequency of approach and the cumulative time of approach to assess the ability to trend social (i.e., reflect the "social intent" as described herein).

As shown in fig. 1, the approach frequency of each experimental example was not significantly different from that of experimental example 1, the approach frequency of experimental example 7 was increased in the trend of experimental example 2 and experimental example 3, but not significantly different, and the approach frequency index of experimental example 4, experimental example 5 and experimental example 6 was significantly increased. In comparison with example 3, example 6 had an increasing tendency but no significance. The approach frequency of experimental example 6 was significantly increased compared to experimental example 7.

As shown in fig. 2, the approach times of the respective examples were not significantly different from those of example 1, but only the approach times of example 6 were significantly increased, and the approach frequencies of example 6 were significantly increased from those of example 3 and example 7.

In conclusion, in the aspect of social interaction tendencies, under the experimental dosage, the independent intervention of the nervonic acid has no obvious influence on the approaching frequency and the approaching accumulation time, DHA and ARA intervention groups with different proportions have influence on the approaching frequency, the combined intervention of the DHA, the ARA and the nervonic acid has obvious increase in the approaching frequency and the approaching accumulation time, the nutritional combination of the DHA, the ARA and the nervonic acid is prompted to have influence on the development of nerves and brains, the social interaction tendencies is promoted, and a certain synergistic technical effect exists in the approaching frequency and the approaching accumulation time.

(2) Social interaction assessment

Social interaction assessment is an assessment of how often, how long, and how long an experimental animal actually socially takes place, most intuitively representing the social ability of an individual (i.e., reflecting the "social ability" described herein, and more particularly including social interaction ability and/or social fitness ability), with the frequency of physical contact, the cumulative time of physical contact, the frequency of relative movement, and the cumulative time of relative movement.

As shown in fig. 3, the body contact frequencies of the respective test examples were not significantly different from those of the test example 1, but the test examples 3, 5 and 6 tended to increase. As shown in fig. 4, the body contact cumulative time of each experimental example was significantly reduced in experimental example 7, and the body contact cumulative time of experimental example 3 was significantly increased, but not significantly reduced, in experimental example 2, experimental example 4, and experimental example 5, respectively, compared with experimental example 1. The body contact cumulative time of experimental example 6 was significantly increased compared to experimental examples 3 and 7.

As shown in fig. 5, the relative movement frequency of each example was not significantly different from that of example 1, but significantly increased in examples 2, 5 and 7, and in examples 3, 4 and 6. In example 6, there was no significant increase in the relative movement frequency compared to example 3, and in example 6, there was a significant increase in the relative movement frequency compared to example 7. As shown in fig. 6, the relative movement cumulative time of each example was decreased in example 2 and example 7, compared to example 1, and the relative movement cumulative time of example 6 was significantly increased without significant difference in example 3, example 4 and example 5. The relative movement cumulative time of experimental example 6 is significantly increased compared to experimental examples 3 and 7.

On social interaction indexes, under the experimental dosage, the independent intervention of the nervonic acid has no obvious influence on the body contact frequency and the relative movement frequency, the body contact accumulation time and the relative movement accumulation time are reduced, the influence of DHA and ARA intervention groups with different proportions on the body contact frequency, the body contact accumulation time, the relative movement frequency and the relative movement accumulation time is different, the influence of DHA and ARA on social interaction is prompted to be related to the proportion, the body contact frequency, the body contact accumulation time, the relative movement frequency and the relative movement accumulation time are obviously increased after the combined dry and dry of the DHA, the ARA and the nervonic acid, the nutritional combination of the DHA, the ARA and the nervonic acid is prompted to have an effect on the development of nerves and brains, and a certain synergistic technical effect exists on the body contact frequency, the body contact accumulation time, the relative movement frequency and the relative movement accumulation time of the social interaction indexes.

Compared with experimental example 1, experimental examples 2-5 are reinforced with DHA and ARA in different proportions on the basis of normal diet, and the result shows that experimental examples 2-5 are increased in the approach frequency, but only experimental examples 4 and 5 are significantly different, experimental examples 2-5 are not significantly different in the approach accumulation time, but experimental examples 3-5 are increased in trend, experimental examples 2-5 are not significantly different in the body contact frequency and the body contact accumulation time, but experimental examples 3-5 are increased in trend, experimental examples 2, experimental examples 4 and experimental examples 5 are not significantly different in the relative movement frequency and the relative movement frequency accumulation time, but experimental examples 3-5 are increased in the relative movement frequency and the relative movement frequency accumulation time of experimental examples 3-5 are increased in trend. The influence of DHA and ARA in different proportions on social behavior is different, and in the experimental example, the DHA: ARA mass ratio of experimental example 3 is 1:1, which is the optimal ratio of DHA to ARA.

Compared with experimental example 1, experimental example 7 is to strengthen the nervonic acid on the basis of normal diet, and the result shows that under the experimental dosage and proportion of the invention, the independent strengthening of the nervonic acid has no obvious influence on the approach frequency, the body contact frequency and the relative movement frequency, but the approach accumulated time, the body contact accumulated time and the relative movement accumulated time can be reduced.

Compared with experimental example 1, experimental example 6 is used for strengthening DHA, ARA and nervonic acid on the basis of normal diet, and the result shows that the intervention of experimental example 6 has a remarkable improvement on social interaction tendencies (approach frequency, approach accumulated time) and social interactions (body contact frequency, body contact accumulated time, relative movement frequency and relative movement accumulated time), has a remarkable increase effect on the approach frequency, the approach accumulated time, the body contact accumulated time, the relative movement frequency and the relative movement accumulated time compared with experimental example 7 for strengthening nervonic acid alone, has a remarkable increase effect on the approach accumulated time, the body contact accumulated time and the relative movement accumulated time compared with the DHA and the ARA which are strengthened alone, and has a remarkable increase trend on the approach frequency, the body contact frequency and the relative movement frequency.

According to the result, the DHA, ARA and the nervonic acid are combined to intervene under the condition of a specific proportion to achieve the optimal nutrition effect on the cerebral nerves and the cerebral functions, the combined intervention has an increasing effect on the approach frequency, the approach accumulation time, the body contact frequency, the body contact accumulation time, the relative movement frequency and the relative movement accumulation time, the nutrition combination of the DHA, the ARA and the nervonic acid is prompted to have an effect on the development of the nerves and the cerebral, the social interaction trend and the social interaction are promoted, and a certain synergistic technical effect exists.

The previous description of the embodiments is provided to facilitate a person of ordinary skill in the art in order to make and use the present invention. It will be apparent to those skilled in the art that various modifications can be readily made to these embodiments and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above-described embodiments, and those skilled in the art, based on the present disclosure, should make improvements and modifications without departing from the scope of the present invention.

Claims

1. A special medical purpose formula food, comprising a composition of DHA, ARA and neuraminic acid, wherein the mass ratio of DHA to ARA is 0.2-5:1, and the mass ratio of the total amount of DHA and ARA to neuraminic acid is 0.8-20:1;

Among them, based on the dry matter weight of the special medical purpose formula food, the protein content is 10-16g/100g, the fat content is 21-32g/100g, and the carbohydrate content is 50-58g/100g. The special medical purpose formula food is selected from one or more of the following: lactose-free formula or low-lactose formula food for infants, partially hydrolyzed milk protein formula food for infants, deeply hydrolyzed milk protein formula food for infants, amino acid formula food for infants, formula food for premature/low birth weight infants, breast milk nutritional supplements, formula food for infant amino acid metabolism disorders, complete nutrition formula food for food protein allergy, complete nutrition formula food for inflammatory bowel disease, complete nutrition formula food for gastrointestinal absorption disorders, and complete nutrition formula food for abnormal fatty acid metabolism.

2. The special medical purpose formula food according to claim 1, wherein, measured by the amount of ARA in the DHA, ARA and neuraminic acid composition, the amount of ARA contained in the special medical purpose formula food is 10-420 mg/100 g of food dry matter, preferably, the amount of ARA contained in the special medical purpose formula food is 15-400 mg/100 g of food dry matter.

3. The special medical purpose formula food according to claim 2, wherein the special medical purpose formula food is a partially hydrolyzed infant milk protein formula food or an extensively hydrolyzed infant milk protein formula food; the total protein in the partially hydrolyzed infant milk protein formula food includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 30% of the total protein, preferably more than 40%; the total protein in the extensively hydrolyzed infant milk protein formula food includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 70% of the total protein, preferably more than 80%.

4. The special medical purpose formula food according to claim 3, wherein, based on 1000 parts by weight of the infant milk protein partially hydrolyzed formula food, the raw materials include:

7 to 50 parts by weight of a compound nutrient comprising calcium powder, vitamins and minerals;

5. The special medical purpose formula food according to claim 3, wherein, based on 1000 parts by weight of the infant milk protein extensively hydrolyzed formula food, the raw materials include:

7 to 80 parts by weight of a compound nutrient comprising calcium powder, vitamins and minerals;

DHA 2-15 parts by weight;

ARA 3-22 parts by weight;

Nucleotides 0-1 parts by weight.

6. The special medical purpose formula food according to claim 4 or 5, wherein the dosage of each component of the compound nutrient containing calcium powder, vitamins and minerals is:

Component 1: complex vitamins, wherein each gram of complex vitamins contains:

Taurine: 25-340 mg;

Vitamin A: 1700～5800μgRE;

Vitamin D: 25-70 μg;

Vitamin _B1 : 2000～6800μg;

Vitamin _B2 : 3000～6900μg;

Vitamin B ₆ : 1700～4000μg;

Vitamin B ₁₂ : 8-20 μg;

Vitamin K ₁ : 200-700 μg;

Vitamin C: 0-700 mg;

Vitamin E: 10-70 mg α-TE;

Nicotinamide: 10000～41550μg;

Folic acid: 350-920 μg;

Biotin: 70-245 μg;

Pantothenic acid: 7100-25230 μg;

Inositol: 0-250mg;

L-Carnitine: 0-60mg;

Component 2: Mineral II, wherein each gram of Mineral II contains: Sodium: 40-100 mg;

Potassium: 200-500 mg;

Component 3: Mineral III, including per gram of Mineral II: Calcium: 200-500 mg;

Phosphorus: 75-300 mg;

Component 4: Mineral 1, wherein per gram of Mineral 1: Iron: 20-110 mg;

Zinc: 23-90 mg;

Copper: 2000-4180 μg;

Iodine: 500-995 μg;

Selenium: 0-200 μg;

Manganese: 0-579 μg;

Component 5: compound magnesium chloride, wherein per gram of magnesium chloride: magnesium: 80-170 mg;

Component 6: Choline chloride, wherein per gram of choline chloride:

Choline: 200-950 mg.

7. The method for preparing the special medical purpose formula food according to any one of claims 1 to 6, wherein the method comprises: using a wet or dry production process to mix the DHA, ARA and neuraminic acid composition with other raw materials in the special medical purpose formula food to prepare the special medical purpose formula food;

Preferably, the steps include:

S01: Mixing: various powder raw materials are added to the powder mixing tank through the air delivery system after being measured according to the formula, and stored to obtain powder raw materials to be vacuum-absorbed; the powder raw materials to be vacuum-absorbed in the powder mixing tank are sucked into the vacuum mixing tank through the vacuum system; the oil specified in the formula is placed in the oiling room according to the formula requirements, and the temperature of the oiling room should be maintained at 50-90°C. After the oil is dissolved, it is pumped into the mixed oil storage tank through the oil pump and flow meter according to the formula ratio requirements to obtain mixed oil; the mixed oil is stored in the oil storage tank at a temperature of 40-50°C and a storage time of 0-12 hours to prevent fat oxidation. According to the formula requirements, the mixed oil is pumped into the mixing tank through the oil pump; calcium powder, minerals, vitamins, etc. are added separately, and 100-200kg of pure water are used to dissolve them separately, and then pumped into the wet mixing tank. After each type is added, 50-150kg of pure water is used to rinse the adding tank and pipeline to obtain a mixed liquid;

S02: Filtration: The mixed feed liquid is filtered through a filter to remove physical impurities in the raw materials to obtain a filtered feed liquid;

S03: Homogenization: The filtered liquid is homogenized by a homogenizer, the first-stage pressure is 105±5bar, and the second-stage pressure is 32±3bar, the fat globules are mechanically treated, and they are dispersed into uniform fat globules to obtain a homogenized liquid;

S04: Cooling and sterilization: The homogenized liquid enters the plate heat exchanger for cooling: cooled to 5-20°C, temporarily stored in the pre-storage tank, and enters the next process in 0-6 hours. The agitator is turned on according to the set requirements. Double-effect concentration is used during production, the sterilization temperature is ≥83°C, the sterilization time is 25 seconds, and the discharge concentration is 48%-52% dry matter to obtain concentrated milk;

S05: Concentrated milk storage, preheating filtration, spray drying: The concentrated milk is temporarily stored in the concentrated milk balance tank, preheated to 60-70℃ by the scraper preheater, filtered through a filter with a pore size of 0.5-1.5mm, and then pumped into the drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required. The inlet air temperature is 165-180℃, the exhaust air temperature is 75-90℃, the high-pressure pump pressure is 160-210bar, and the tower negative pressure is -4 to -2mbar;

S06: Fluidized bed drying and cooling: The powder coming out of the drying tower is dried twice in a fluidized bed (primary stage), and then cooled to 25-30°C in a fluidized bed (secondary stage). At the same time, human milk oligosaccharide is mixed with a carrier and heated to 60-65°C. Under the action of compressed air, it is evenly dispersed on the surface of the powder. According to the formula requirements, DHA, ARA, nucleotides, and bifidobacteria are weighed and sealed in bags to obtain weighed DHA, ARA, nucleotides, and bifidobacteria;

S07: Powder screening: Mix the weighed DHA, ARA, nucleotides, bifidobacteria and milk powder in a dry mixer, pass through a vibrating screen to make the particle size of the milk powder uniform, discard the powder residue, collect the powder in a sterilized powder collecting box, and transport it from the powder discharging room to the powder loading room to obtain special medical purpose formula food.

8. Use of the special medical purpose formula food according to any one of claims 1 to 6 in the preparation of a product that helps to enhance and/or improve the social behavior of an individual.

9. The application according to claim 8, wherein said enhancing and/or improving individual social behavior comprises: enhancing individual social willingness and/or social ability;

Preferably, the social ability includes social interaction ability and/or social adaptability.

10. The use according to claim 8 or 9, wherein the individual is an infant or a young child.